Regeneron Pharmaceuticals Aktie

Kaufen

Verkaufen

Handeln Handeln

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

488,30 EUR +4,90 EUR +1,01 %

30.07.2025

BMN

550,11 USD -4,70 USD -0,85 %

nachbörslich01:54:17

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.52,71 Mrd. EUR

KGV18,58Div. Rendite0,00%

WKN881535

ISINUS75886F1075

SymbolREGN

Regeneron Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

04.10.22PR NewswireRegeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022

03.10.22PR NewswireRegeneron Elects Dr. Craig B. Thompson to Board of Directors

30.09.22PR NewswireAflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO

28.09.22PR NewswireDupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

16.09.22PR NewswireIntellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

15.09.22PR NewswireRegeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

12.09.22PR NewswirePositive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM

12.09.22PR NewswireFianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 In...

10.09.22PR NewswireNovel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors

09.09.22PR NewswireRegeneron Announces Investor Call and Webcast at ESMO 2022

08.09.22PR NewswireDupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis

08.09.22PR NewswireAflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals

05.09.22PR NewswireLate-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma

05.09.22PR NewswireESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers

25.08.22PR NewswireRegeneron Announces Investor Conference Presentations

03.08.22PR NewswireRegeneron Reports Second Quarter 2022 Financial and Operating Results

03.08.22PR NewswireNovel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (m...

Regeneron Pharmaceuticals News

Regeneron Pharmaceuticals News: auf dieser Seite finden Sie alle Regeneron Pharmaceuticals News und Nachrichten zur Regeneron Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Regeneron Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Regeneron Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.